Huikai Li

机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0003-4864-4991

发表论文 100 篇 · 总被引 1133 次 · h-index 19

代表论文

• Recent advances in the bench-to-bedside translation of cancer nanomedicines (2024 · Acta Pharmaceutica Sinica B · 被引 96)
• Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study (2023 · Frontiers in Immunology · 被引 50)
• Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation (2024 · Cell Reports Medicine · 被引 26)
• A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma (2023 · Journal of Hepatocellular Carcinoma · 被引 25)
• Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial (2024 · Neoplasma · 被引 22)
• Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth (2024 · Cancer Letters · 被引 12)